Search
Aurinia Pharmaceuticals Inc
AUPHAdd to Watchlist
15.280USD
-0.560-3.54%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.97BMarket Cap
6.86P/E TTM
More Details of Aurinia Pharmaceuticals Inc Company
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Aurinia Pharmaceuticals Inc Info
Ticker SymbolAUPH
Company nameAurinia Pharmaceuticals Inc
IPO dateJul 16, 2001
CEOGreenleaf (Peter S)
Number of employees130
Security typeOrdinary Share
Fiscal year-endJul 16
Address#140, 14315 - 118 Avenue
CityEDMONTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeT5L 4S6
Phone12507442487
Websitehttps://www.auriniapharma.com
Ticker SymbolAUPH
IPO dateJul 16, 2001
CEOGreenleaf (Peter S)
Company Executives of Aurinia Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.05M
+31.87%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
273.64K
+37.03%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
28.53K
+59.79%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-21.87%
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Max) Donley
Mr. Matthew (Max) Donley
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey A. Bailey
Mr. Jeffrey A. Bailey
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.05M
+31.87%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
273.64K
+37.03%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
28.53K
+59.79%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-21.87%
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew (Max) Donley
Mr. Matthew (Max) Donley
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
US
263.84M
93.21%
Japan
19.21M
6.79%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
9.51%
BlackRock Institutional Trust Company, N.A.
5.12%
ILJIN SNT Co., Ltd.
5.08%
New Enterprise Associates (NEA)
3.09%
Arrowstreet Capital, Limited Partnership
2.63%
Other
74.56%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
9.51%
BlackRock Institutional Trust Company, N.A.
5.12%
ILJIN SNT Co., Ltd.
5.08%
New Enterprise Associates (NEA)
3.09%
Arrowstreet Capital, Limited Partnership
2.63%
Other
74.56%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.10%
Investment Advisor/Hedge Fund
16.56%
Investment Advisor
15.90%
Corporation
5.08%
Research Firm
3.71%
Venture Capital
3.09%
Individual Investor
2.61%
Pension Fund
0.70%
Family Office
0.45%
Other
33.80%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
483
74.86M
58.21%
-419.17K
2025Q4
442
66.87M
49.23%
+66.21K
2025Q3
456
66.87M
50.55%
+7.38M
2025Q2
441
59.25M
53.54%
-3.86M
2025Q1
434
64.06M
48.83%
-3.20M
2024Q4
431
60.29M
49.51%
-113.45K
2024Q3
429
60.37M
47.88%
+2.19M
2024Q2
432
58.67M
47.42%
+718.51K
2024Q1
426
57.94M
45.47%
-7.82M
2023Q4
439
56.12M
43.33%
+3.78M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
12.23M
9.2%
+900.00K
+7.94%
Mar 23, 2026
BlackRock Institutional Trust Company, N.A.
6.59M
4.95%
+369.31K
+5.94%
Dec 31, 2025
ILJIN SNT Co., Ltd.
6.54M
4.91%
-984.75K
-13.10%
Aug 12, 2025
New Enterprise Associates (NEA)
3.97M
2.99%
--
--
Dec 31, 2025
Arrowstreet Capital, Limited Partnership
3.39M
2.55%
+13.17K
+0.39%
Dec 31, 2025
Two Sigma Investments, LP
3.27M
2.46%
+1.44M
+78.36%
Dec 31, 2025
State Street Investment Management (US)
2.50M
1.88%
-191.76K
-7.12%
Dec 31, 2025
Renaissance Technologies LLC
1.59M
1.2%
+140.53K
+9.69%
Dec 31, 2025
Marshall Wace LLP
1.57M
1.18%
+91.83K
+6.19%
Dec 31, 2025
D. E. Shaw & Co., L.P.
1.53M
1.15%
+622.35K
+68.40%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.56%
Janus Henderson Small Cap Growth Alpha ETF
2.33%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.09%
ALPS Medical Breakthroughs ETF
0.7%
ProShares Ultra Nasdaq Biotechnology
0.26%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.26%
SPDR S&P International Small Cap ETF
0.2%
Vanguard US Multifactor ETF
0.18%
Invesco Nasdaq Biotechnology ETF
0.17%
Avantis US Small Cap Equity ETF
0.16%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.56%
Janus Henderson Small Cap Growth Alpha ETF
Proportion2.33%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion1.09%
ALPS Medical Breakthroughs ETF
Proportion0.7%
ProShares Ultra Nasdaq Biotechnology
Proportion0.26%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.26%
SPDR S&P International Small Cap ETF
Proportion0.2%
Vanguard US Multifactor ETF
Proportion0.18%
Invesco Nasdaq Biotechnology ETF
Proportion0.17%
Avantis US Small Cap Equity ETF
Proportion0.16%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
